S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Biden To Unleash "Choke Point" Operation On America? (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Biden To Unleash "Choke Point" Operation On America? (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Biden To Unleash "Choke Point" Operation On America? (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Biden To Unleash "Choke Point" Operation On America? (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$24.17
+0.46 (+1.94%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.57
$24.52
50-Day Range
$18.96
$24.56
52-Week Range
$8.85
$26.35
Volume
1.56 million shs
Average Volume
2.59 million shs
Market Capitalization
$3.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.30

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
12.9% Upside
$27.30 Price Target
Short Interest
Bearish
7.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of IVERIC bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.39 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.68) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

Medical Sector

955th out of 1,005 stocks

Pharmaceutical Preparations Industry

459th out of 486 stocks


ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Guru Fundamental Report for ISEE
Q4 2022 IVERIC bio Inc Earnings Call
IVERIC Bio (ISEE) Q4 2022 Earnings Call Transcript
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Bank of America Securities Keeps Their Buy Rating on IVERIC bio (ISEE)
H.C. Wainwright Keeps Their Buy Rating on IVERIC bio (ISEE)
Iveric bio: Building Momentum Around Zimura, Rate Buy
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
3/01/2023
Today
3/25/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.30
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+12.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-185,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.43 per share

Miscellaneous

Free Float
133,420,000
Market Cap
$3.31 billion
Optionable
Optionable
Beta
1.09

Key Executives

  • Glenn P. SblendorioGlenn P. Sblendorio
    Chief Executive Officer & Director
  • Pravin U. DugelPravin U. Dugel
    President & Director
  • Keith WestbyKeith Westby
    Chief Operating Officer & Senior Vice President
  • David F. Carroll
    Chief Financial Officer, Treasurer & Senior VP
  • Xiao Ping Dai
    Chief Technical Officer













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2023?

9 brokerages have issued 12 month price objectives for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's share price to reach $27.30 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2023?

IVERIC bio's stock was trading at $21.41 at the beginning of the year. Since then, ISEE stock has increased by 12.9% and is now trading at $24.17.
View the best growth stocks for 2023 here
.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) issued its earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.10. During the same quarter in the prior year, the firm earned ($0.29) earnings per share.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.59%), Price T Rowe Associates Inc. MD (4.01%), Alliancebernstein L.P. (3.51%), Braidwell LP (2.77%), Point72 Asset Management L.P. (2.46%) and Deutsche Bank AG (2.01%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $24.17.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $3.31 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 3/25/2023 by MarketBeat.com Staff